Trust Signals
- No financial relationship with any Florida clinic listed or referenced on this page.
- All evidence claims are graded; speculative claims are labeled as such.
-
Yes, with important caveats. Florida-licensed physicians can prescribe compounded peptides through state-licensed 503A or federally registered 503B pharmacies. However, the FDA has placed several peptides, including BPC-157 and CJC-1295, on its list of drugs that may not be compounded, which limits what a compliant clinic can legally dispense as of 2024 to 2025.
See your personalized options in about 2 minutes. Free and private. See my options →
What peptides are currently legal to prescribe in Florida?
FDA-approved peptides (semaglutide, tirzepatide, bremelanotide, sermorelin) remain prescribable. Several compounded peptides such as BPC-157, TB-500, and CJC-1295 are on the FDA difficult-to-compound or prohibited list, which means compliant Florida pharmacies cannot compound them. Regulations change frequently; verify current status with the pharmacy's compliance officer before any prescription is written.How much does peptide therapy cost at a Florida clinic?
Costs vary widely. An initial consultation may run $150 to $400. Monthly compounded peptide protocols commonly range from $200 to $600 depending on the compound, dose, and whether labs are included. FDA-approved GLP-1 peptides like semaglutide carry additional pharmaceutical costs. Most peptide therapy is not covered by insurance.What should I ask a Florida peptide clinic before signing up?
Ask which 503A or 503B pharmacy supplies the compounds and request a certificate of analysis for the specific lot you will receive. Ask the prescribing physician what peer-reviewed evidence supports the protocol, what monitoring labs are ordered at baseline and follow-up, and what their process is if the FDA changes compounding rules mid-protocol.Does peptide therapy actually work for weight loss?
FDA-approved GLP-1 receptor agonist peptides (semaglutide, tirzepatide) have strong Phase 3 trial evidence for weight loss in adults with obesity. Other compounded peptides marketed for weight loss have no equivalent human RCT evidence. The evidence gap between approved and unapproved peptides is substantial, and any clinic that equates them is overstating the data.What are the red flags at a Florida peptide clinic?
Red flags include: no in-person or synchronous telehealth physician evaluation, no baseline lab work, inability to provide a COA for compounds dispensed, claims that compounded peptides are equivalent to FDA-approved drugs, and dispensing peptides that the FDA has placed on its prohibited compounding list.Is sermorelin a legitimate peptide for adults in Florida?
Sermorelin is FDA-approved for pediatric growth hormone deficiency and has been used off-label in adults for growth hormone secretagogue effects. It remains on the 503A compoundable list as of current guidance, unlike several other secretagogues. Evidence for adult anti-aging outcomes is modest and mostly from small or observational studies, not large RCTs.How do I read a peptide certificate of analysis?
A COA from a reputable compounding pharmacy should include: identity confirmation (HPLC or mass spectrometry), purity percentage with the method used, endotoxin testing result (LAL method), sterility test result, lot number that matches your vial, and the issuing lab's accreditation. If any of these fields are absent or show an unaccredited third-party lab, treat it as a red flag.Can I get peptide therapy via telehealth in Florida?
Florida law allows synchronous telehealth prescribing by licensed Florida physicians. A proper telehealth peptide consultation should still include a medical history review, a review of recent labs or an order for baseline labs, and informed consent documentation. Asynchronous questionnaire-only prescribing without a live physician evaluation is a compliance and safety concern.What labs should a Florida peptide clinic order before starting therapy?
At minimum, a responsible clinic should review or order: comprehensive metabolic panel, CBC, lipid panel, fasting insulin and glucose or HbA1c, IGF-1 if growth hormone secretagogues are prescribed, and testosterone or hormone panel if peptides are part of a hormone optimization protocol. The specific panel depends on the peptide and the patient's indication.Are there Florida Board of Medicine rules specific to peptide therapy?
The Florida Board of Medicine does not have a peptide-specific rule, but general standards of care apply: documented diagnosis or clinical indication, informed consent, appropriate follow-up, and prescribing only from licensed pharmacies. Violations of these standards can result in disciplinary action regardless of whether the substance is approved or compounded.Sources
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205-216.
- U.S. Food and Drug Administration. Compounding Laws and Policies: 503A Compounding. FDA.gov. Accessed 2026.
- U.S. Food and Drug Administration. Difficult to Compound Drug Products List (Section 503A). FDA.gov. Updated 2024.
- U.S. Food and Drug Administration. Memorandum Regarding Compounding of Certain Bulk Drug Substances Under Section 503A. 2023 to 2024.
- Florida Statute 456.47: Telehealth. Florida Legislature. Accessed 2026.
- Florida Department of Health, Division of Medical Quality Assurance. Practitioner License Search. flhealthsource.gov.
- Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging. 2006;1(4):307-308.
- United States Pharmacopeia. General Chapter 797: Pharmaceutical Compounding, Sterile Preparations. USP-NF. Current edition.
- Palatin Technologies. Clinical Study Results for Bremelanotide (PT-141) in Female Hypoactive Sexual Desire Disorder. Published in support of FDA NDA 210557. 2019.
- Florida Board of Pharmacy. Compounding Regulations. Florida Administrative Code Chapter 64B16-28. Accessed 2026.
Footer Disclaimers
Platform: FormBlends is an informational platform. This page does not constitute medical advice, diagnosis, or treatment. Consult a licensed physician before initiating any peptide protocol.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Research Compound and Compounded Medication Notice: Several peptides discussed on this page are investigational or compounded substances not approved by the FDA for the indications described. Their safety and efficacy have not been established in large controlled human trials. Regulatory status changes frequently; verify current FDA and state pharmacy board guidance before prescribing or using these substances.
Results: Individual results from any peptide therapy vary substantially based on dose, compounding quality, individual physiology, adherence, and co-interventions. Results described in clinical trials may not be reproducible in compounded products or clinical practice settings.
Trademark: Ozempic, Wegovy, Zepbound, Mounjaro, and Addyi are registered trademarks of their respective owners. FormBlends has no affiliation with these trademark holders. Brand names are used for identification purposes only.
Related peptide guides
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →